問卷

TPIDB > Search Result > Study Site

Study Site



Taipei Veterans General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

篩選

List

2252Cases

2025-11-01 - 2034-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Belzutifan (MK-6482) Zanzalintinib (XL092)

Participate Sites
4Sites

Not yet recruiting1Sites

2023-09-01 - 2027-04-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-09-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-09-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2023-10-01 - 2026-12-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting3Sites

2023-10-01 - 2033-02-05

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2023-10-10 - 2027-07-14

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-10-31 - 2027-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-10-31 - 2027-08-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting7Sites

2023-11-01 - 2026-10-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites